Psoriatic Arthritis Epidemiology Analysis and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995

Psoriatic Arthritis Report Overview

In 2023, there were 1,547,313 diagnosed prevalent cases of psoriatic arthritis across the 7MM. Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive and can lead to severe joint damage and disability. The disease is considered rare in the general population, but PsA affects up to 30% of people with psoriasis.

The psoriatic arthritis market research report provides an overview of the risk factors, comorbidities, and global trends of psoriatic arthritis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for diagnosed incident cases of PsA and a 10-year forecast of diagnosed prevalent cases of PsA segmented by sex and age.

Buy the Full Report for More Psoriatic Arthritis Market Epidemiology Insights
Download a Free Report Sample

Market Size (2023) 1,547,313 Cases
Forecast Period 2023-2033
Key Countries ·       The US

·       France

·       Germany

·       Spain

·       Italy

·       The UK

·       Japan

Key Sex Segments ·       Men

·       Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Psoriatic Arthritis Market Segmentation by Country

The key countries across the 7MM are the US, France, Germany, Spain, Italy, the UK, and Japan. In 2023, the US accounted for the highest number of diagnosed prevalent cases of psoriatic arthritis in the 7MM. The main growth driver of the diagnosed prevalent cases of PsA across the 7MM is the overall increase in the diagnosis rate of PsA.

Psoriatic Arthritis Market Analysis by Country, 2023 (%)

Psoriatic Arthritis Market Analysis by Country, 2023 (%)

Buy the Full Report for More Country Insights into the Psoriatic Arthritis Market
Download a Free Report Sample

Psoriatic Arthritis Market Segmentation by Sex Type

Based on sex type, the market can be segmented into men and women. In 2023, the number of diagnosed prevalent cases of PsA was higher in men than in women across the 7MM combined. The UK showed the smallest difference in the number of diagnosed prevalent cases between women and men.

Psoriatic Arthritis Market Analysis by Sex Type, 2023 (%)

Psoriatic Arthritis Market Analysis by Sex Type, 2023 (%)

Buy the Full Report for More Sex Type Insights into the Psoriatic Arthritis Market

Download a Free Report Sample

Segments Covered in the Report

Psoriatic Arthritis Country Outlook (Diagnosed Prevalent Cases, 2023)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan

Psoriatic Arthritis Sex Type Outlook (Diagnosed Prevalent Cases, 2023)

  • Men
  • Women

Scope

This report provides an overview of the risk factors, comorbidities, and global and historical trends for PsA across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of PsA and a 10-year forecast of diagnosed prevalent cases of PsA segmented by sex and age (beginning at age 18 years and ending at ages 85 years or older) in these markets. This report also includes an assessment of PsA severity, an analysis of diagnosed prevalent cases by subtype based on the Moll and Wright Criteria, data on prevalent PsA cases with comorbidities, and a forecast of prevalent PsA cases with psoriasis. The epidemiology model will provide additional clinically relevant segmentations, including a forecast for the total prevalent cases (diagnosed and undiagnosed) of PsA.

Reasons to Buy

The psoriatic arthritis epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global PsA market.
  • Quantify patient populations in the global PsA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PsA therapeutics in each of the markets covered.

Table of Contents

  • About GlobalData
  • List of Contents
  • List of Tables
  • List of Figures
  • 1 Psoriatic Arthritis: Executive Summary

    • 1.1 Catalyst
    • 1.2 Related reports
    • 1.3 Upcoming reports

  • 2 Epidemiology

    • 2.1 Disease background
    • 2.2 Risk factors and comorbidities
    • 2.3 Global and historical trends
    • 2.4 Forecast methodology

      • 2.4.1 Sources
      • 2.4.2 Forecast assumptions and methods
      • 2.4.3 Diagnosed incident cases of PsA
      • 2.4.4 Diagnosed prevalent cases of PsA
      • 2.4.5 Diagnosed prevalent cases of PsA by type
      • 2.4.6 Diagnosed prevalent cases of PsA by severity
      • 2.4.7 Diagnosed prevalent cases of PsA with comorbidity
      • 2.4.8 Diagnosed prevalent cases of PsA with psoriasis

    • 2.5 Epidemiological forecast for PsA (2023–33)

      • 2.5.1 Diagnosed incident cases of PsA
      • 2.5.2 Sex-specific diagnosed incident cases of PsA
      • 2.5.3 Age-specific diagnosed incident cases of PsA
      • 2.5.4 Diagnosed prevalent cases of PsA
      • 2.5.5 Sex-specific diagnosed prevalent cases of PsA
      • 2.5.6 Age-specific diagnosed prevalent cases of PsA
      • 2.5.7 Diagnosed prevalent cases by type
      • 2.5.8 Diagnosed prevalent cases by severity
      • 2.5.9 Diagnosed prevalent cases by comorbidity
      • 2.5.10 Diagnosed prevalent cases of PsA with psoriasis

    • 2.6 Discussion

      • 2.6.1 Epidemiological forecast insight
      • 2.6.2 Limitations of the analysis
      • 2.6.3 Strengths of the analysis

  • 3 Appendix

    • 3.1 Bibliography
    • 3.2 Primary research – prescriber survey
    • 3.3 Primary market research – Key opinion leaders (KOLs) interviewed for this report

      • 3.3.1 KOLs

    • 3.4 About the authors

      • 3.4.1 Epidemiologist
      • 3.4.2 Reviewers
      • 3.4.3 Vice President of Disease Intelligence and Epidemiology
      • 3.4.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

  • 4 Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for PsA

Table 4: 7MM, diagnosed prevalent cases by severity (N), men and women, ages ≥18 years, 2023

Table 5: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: 7MM, diagnosed incident cases of PsA (N), men and women, ages ≥18 years, 2023 and 2033

Figure 2: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages ≥18 years, 2023 and 2033

Figure 3: 7MM, diagnosed incidence of PsA (cases per 100,000 population), men and women, ages ≥18 years, 2023

Figure 4: 7MM, diagnosed prevalence of PsA (%), men and women, ages ≥18 years, 2023

Figure 5: 7MM, sources used and not used to forecast the diagnosed incident cases of PsA

Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of PsA

Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of PsA by type

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PsA with comorbidity

Figure 9: 7MM, diagnosed incident cases of PsA (N), men and women, ages ≥18 years, 2023

Figure 10: 7MM, diagnosed incident cases of PsA by sex (N), ages ≥18 years, 2023

Figure 11: 7MM, diagnosed incident cases of PsA by age (N), men and women, 2023

Figure 12: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages ≥18 years, 2023

Figure 13: 7MM, diagnosed prevalent cases of PsA by sex (N), ages ≥18 years, 2023

Figure 14: 7MM, diagnosed prevalent cases of PsA by age (N), men and women, 2023

Figure 15: 7MM, diagnosed prevalent cases by type (N), men and women, ages ≥18 years, 2023

Figure 16: 7MM, diagnosed prevalent cases by severity (N), men and women, ages ≥18 years, 2023

Figure 17: 7MM, diagnosed prevalent cases of PsA with psoriasis (N), men and women, ages ≥18 years

Frequently asked questions

Psoriatic Arthritis Epidemiology Analysis and Forecast to 2033 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Psoriatic Arthritis Epidemiology Analysis and Forecast to 2033 in real time.

  • Access a live Psoriatic Arthritis Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.